PFS | OS | |||
Characteristic | HR (95% CI) | P | HR (95% CI) | P |
All population (n = 77) | ||||
BCLC staging system, stages A and B vs. stage C | 0.59 (0.30–1.15) | 0.12 | 0.63 (0.33–1.19) | 0.15 |
Tumor size, <5 vs. ≥5 cm | 0.94 (0.70–1.25) | 0.66 | 0.85 (0.59–1.22) | 0.37 |
Serum AFP level | 0.76 (0.38–1.52) | 0.43 | 0.84 (0.58–1.20) | 0.37 |
90Y resin group (n = 41) | ||||
BCLC staging system, stages A and B vs. stage C | 0.85 (0.35–2.03) | 0.71 | 0.49 (0.20–1.19) | 0.12 |
Tumor size, <5 vs. ≥5 cm | 0.52 (0.19–1.42) | 0.20 | 0.62 (0.24–1.63) | 0.33 |
Serum AFP level | 0.85 (0.60–1.20) | 0.35 | 0.65 (0.38–1.11) | 0.11 |
90Y glass group (n = 36) | ||||
BCLC staging system, stages A and B vs. stage C | 0.27 (0.08–0.96) | 0.04 | 0.74 (0.23–2.44) | 0.62 |
Tumor size, <5 vs. ≥5 cm | 1.87 (0.55–6.40) | 0.32 | 0.93 (0.30–2.93) | 0.90 |
Serum AFP level | 1.73 (0.99–3.01) | 0.06 | 1.72 (1.02–2.90) | 0.04 |
HR = hazard ratio.